A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Brief Summary:
This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells.
- The name of the study intervention involved in this study is regorafenib.
Detailed Description:
This is a phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.
The FDA (the U.S. Food and Drug Administration) has approved regorafenib as a treatment for metastatic colorectal cancer and locally advanced, unresectable or metastatic gastrointestinal stromal tumor. Regorafenib has not been approved for treatment against thyroid cancer.
Regorafenib is an oral anti-tumor agent that blocks activity of a specific kind of protein involved in normal cellular functions and in pathologic processes such as tumor formation and maintenance.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 33 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Actual Study Start Date: January 2016
Estimated Primary Completion Date: December 2021
Estimated Study Completion Date: October 2022
Arm:
- Experimental: Regorafenib
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 33 |
| Actual Study start date | 01 January 2016 |
| Estimated Study Completion Date | 01 October 2022 |